Allowing developments on tech that will kill cancer based on their genetics
Key points from article :
Biotech startup OncoSenX is raising more cash to help support its pipeline of therapeutics.
Tech targets solid tumors based on a patented lipid nanoparticle gene delivery system.
And also on a highly targeted DNA payload.
Company just extended its oversubscribed SAFE to allow for more capital.
Also planning on raising a $30 million Series A round to support its Phase I clinical trial.
Click on resource name for more details.
Drug development company focused on the senolytic technology to fight age-related diseases
Late stage pre-clinical cancer company targeting solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.
